Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance.

Heydt, Carina; Michels, Sebastian; Thress, Kenneth S; Bergner, Sven; Wolf, Jürgen; Buettner, Reinhard

Heydt, Carina; Michels, Sebastian; Thress, Kenneth S; Bergner, Sven; Wolf, Jürgen; Buettner, Reinhard.

Afiliação

Heydt C; Molecular Pathological Diagnostics, Institute of Pathology, University Hospital Cologne, Cologne, Germany.
Michels S; Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, Cologne, Germany.
Thress KS; Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, Cologne, Germany.
Bergner S; Department I of Internal Medicine, Center for Integrated Oncology Köln-Bonn, University Hospital of Cologne, Cologne, Germany.
Wolf J; Translational Science, Oncology iMED, AstraZeneca, Waltham, MA, USA.
Buettner R; Medical Affairs, AstraZeneca Oncology, Wedel, Germany.

Oncotarget ; 9(20): 15418-15434, 2018 Mar 16.

Article em En | MEDLINE | ID: mdl-29632655

Palavras-chave

epidermal growth factor receptor (EGFR); non-small-cell lung cancer (NSCLC); resistance; tumor heterogeneity; tyrosine kinase inhibitor (TKI)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Oncotarget Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Alemanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google